ChimerixCMRX
CMRX
About: Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Employees: 81
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
593% more capital invested
Capital invested by funds: $34.5M [Q3] → $239M (+$205M) [Q4]
119% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $549K
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
10% more funds holding
Funds holding: 63 [Q3] → 69 (+6) [Q4]
9.15% more ownership
Funds ownership: 41.4% [Q3] → 50.54% (+9.15%) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 21
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8.50
0%
upside
Avg. target
$9.35
10%
upside
High target
$11
29%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Jones Trading Soumit Roy 19% 1-year accuracy 3 / 16 met price target | 0%upside $8.55 | Hold Downgraded | 6 Mar 2025 |
Jefferies Maury Raycroft 0% 1-year accuracy 0 / 8 met price target | 0%downside $8.50 | Hold Downgraded | 5 Mar 2025 |
HC Wainwright & Co. Edward White 22% 1-year accuracy 6 / 27 met price target | 29%upside $11 | Neutral Downgraded | 5 Mar 2025 |
Financial journalist opinion
Based on 15 articles about CMRX published over the past 30 days
Positive
Seeking Alpha
2 days ago
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
Neutral
GlobeNewsWire
1 week ago
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025
Neutral
Business Wire
3 weeks ago
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to.
Neutral
GlobeNewsWire
3 weeks ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).
Neutral
GlobeNewsWire
3 weeks ago
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholders.
Neutral
Zacks Investment Research
3 weeks ago
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Positive
Zacks Investment Research
3 weeks ago
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
Positive
Zacks Investment Research
3 weeks ago
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.
Neutral
PRNewsWire
4 weeks ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
NEW YORK , March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Chimerix, Inc. (NASDAQ: CMRX ), relating to the proposed merger with Jazz Pharmaceuticals.
Neutral
PRNewsWire
4 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chimerix, Inc. (NASDAQ: CMRX)'s sale to Jazz Pharmaceuticals plc for $8.55 per share in cash. If you are a Chimerix shareholder, click here to learn more about your rights and options.
Charts implemented using Lightweight Charts™